10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product Launches
10x Genomics GAAP EPS of -$0.50 in-line, revenue of $141M misses by $1.08M
10x Genomics Reports First Quarter 2024 Financial Results
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
3 Medical Products Stocks Set to Beat This Earnings Season
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.